PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes - PubMed
4 hours ago
- #NSCLC resistance
- #meta-analysis
- #immunotherapy rechallenge
- PD-(L)1 rechallenge strategies for advanced NSCLC show modest OS and PFS benefits but no ORR improvement.
- Benefit is limited to patients with acquired resistance (HR 0.86 for OS), with no benefit for primary resistance.
- Analysis included 10 RCTs (n=3,081) and 106 single-arm trials, with varied ORR in single-arm studies.
- Signals of higher activity were seen in regimens combining VEGF-targeting or chemotherapy, but remain speculative.
- Results are clinically marginal, with limitations due to heterogeneous resistance definitions across trials.